1
|
Pacheco-Ceballos M, Torres-Velázquez MA, Oropeza-Martínez M, Villegas-Velázquez I, Ruiz-Ortega M. Comparación del tiempo de cicatrización entre N-butil cianoacrilato y ácido poliglicólico en caninos sometidos a esterilización. Rev Med Vet Zoot 2019. [DOI: 10.15446/rfmvz.v66n1.79398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
El objetivo de este estudio fue comparar el tiempo de cicatrización entre N-butil cianoacrilato (NBC) y ácido poliglicólico (AC) sobre el cierre tisular en caninos sometidos a operaciones de esterilización. Se realizó un estudio observacional, comparativo y descriptivo sobre una población de 80 perros (Canis familiaris) vivos. Los animales se dividieron en cuatro grupos de 20 perros cada uno según sexo y material de sutura, así: primero grupo, hembras que recibieron NBC; segundo grupo, machos y NBC; tercero grupo, hembras y AC como medio de sutura en piel y cuarto grupo, machos y AC. La técnica quirúrgica en hembras fue oforosalpingohisterectomia y en machos orquiectomia. El tiempo de cierre fue estadísticamente (p < 0,05) menor en los grupos de machos y hembras con el adhesivo NBC comparado con los dos grupos tratados con AC. Se concluye que el NBC es un material seguro y eficaz como medio de fijación tisular en ambas técnicas quirúrgicas que disminuye los días de cierre y recuperación.
Collapse
|
2
|
Orejudo Del Rio M, Rodrigues-Diez RR, Rodrigues-Diez R, Lavoz C, Egido J, Ruiz-Ortega M. P3788Interleukin-17A is involved in renal damage associated with arterial pressure changes. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Orejudo Del Rio
- Foundation Jimenez Diaz, Division of Nephrology, Medicine Department, Autonomous University of Madrid, Madrid, Spain
| | | | | | - C Lavoz
- Austral University of Chile, Division of Nephrology, School of Medicine, Valdivia, Chile
| | - J Egido
- Foundation Jimenez Diaz, Division of Nephrology, Medicine Department, Autonomous University of Madrid, Madrid, Spain
| | - M Ruiz-Ortega
- Foundation Jimenez Diaz, Division of Nephrology, Medicine Department, Autonomous University of Madrid, Madrid, Spain
| |
Collapse
|
3
|
Suarez-Alvarez B, Rodriguez RM, Ruiz-Ortega M, Lopez-Larrea C. BET Proteins: An Approach to Future Therapies in Transplantation. Am J Transplant 2017; 17:2254-2262. [PMID: 28173625 DOI: 10.1111/ajt.14221] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2016] [Revised: 01/13/2017] [Accepted: 01/31/2017] [Indexed: 01/25/2023]
Abstract
In order to develop new efficient therapies for organ transplantation, it is essential to acquire a comprehensive knowledge of the molecular mechanisms and processes, such as immune activation, chronic inflammation, and fibrosis, which lead to rejection and long-term graft loss. Recent efforts have shed some light on the epigenetic regulation associated with these processes. In this context, the bromo and extraterminal (BET) family of bromodomain proteins (BRD2, BRD3, BRD4, and BRDT) have emerged as major epigenetic players, connecting chromatin structure with gene expression changes. These proteins recognize acetylated lysines in histones and master transcription factors to recruit regulatory complex and, finally, modify the transcriptional program. Recent studies indicate that BET proteins are essential in the NF-kB-mediated inflammatory response, during the activation and differentiation of Th17-immune cells, and in profibrotic processes. Here, we review this new body of data and highlight the efficiency of BET inhibitors in several models of diseases. The promising results obtained from these preclinical models indicate that it may be time to translate these outcomes to the transplantation field, where epigenetics will be of increasing value in the coming years.
Collapse
Affiliation(s)
- B Suarez-Alvarez
- Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - R M Rodriguez
- Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - M Ruiz-Ortega
- Cellular Biology of Renal Disease Laboratory, Nephrology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - C Lopez-Larrea
- Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain
| |
Collapse
|
4
|
Orejudo Del Rio M, Garcia-Redondo A, Rodrigues-Diez R, Rodrigues-Diez R, Salaices M, Egido J, Briones A, Ruiz-Ortega M. P6272Implication of Interleukin-17A, cytokine of Th17 response, in vascular damage. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Gómez-Guerrero C, González E, Hernando P, Ruiz-Ortega M, Egido J. Interaction of mesangial cells with IgA and IgG immune complexes: a possible mechanism of glomerular injury in IgA nephropathy. Contrib Nephrol 2015; 104:127-37. [PMID: 8391962 DOI: 10.1159/000422405] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- C Gómez-Guerrero
- Renal Unit, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | | | | | |
Collapse
|
6
|
Gómez-Guerrero C, Alonso J, López-Armada MJ, Ruiz-Ortega M, Gómez-Garre D, Alcazar R, Gonzalez E, Egido J. Potential factors governing extracellular matrix production by mesangial cells: their relevance for the pathogenesis of IgA nephropathy. Contrib Nephrol 2015; 111:45-54. [PMID: 7758346 DOI: 10.1159/000423876] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
7
|
Sanchez-Niño MD, Fernandez-Fernandez B, Perez-Gomez MV, Poveda J, Sanz AB, Cannata-Ortiz P, Ruiz-Ortega M, Egido J, Selgas R, Ortiz A. Albumin-induced apoptosis of tubular cells is modulated by BASP1. Cell Death Dis 2015; 6:e1644. [PMID: 25675304 PMCID: PMC4669784 DOI: 10.1038/cddis.2015.1] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Revised: 12/21/2014] [Accepted: 12/29/2014] [Indexed: 12/25/2022]
Abstract
Albuminuria promotes tubular injury and cell death, and is associated with faster progression of chronic kidney disease (CKD) to end-stage renal disease. However, the molecular mechanisms regulating tubular cell death in response to albuminuria are not fully understood. Brain abundant signal protein 1 (BASP1) was recently shown to mediate glucose-induced apoptosis in tubular cells. We have studied the role of BASP1 in albumin-induced tubular cell death. BASP1 expression was studied in experimental puromycin aminonucleoside-induced nephrotic syndrome in rats and in human nephrotic syndrome. The role of BASP1 in albumin-induced apoptosis was studied in cultured human HK2 proximal tubular epithelial cells. Puromycin aminonucleoside induced proteinuria and increased total kidney BASP1 mRNA and protein expression. Immunohistochemistry localized the increased BASP1 to tubular cells. BASP1 expression colocalized with deoxynucleotidyl-transferase-mediated dUTP nick-end labeling staining for apoptotic cells. Increased tubular BASP1 expression was observed in human proteinuric nephropathy by immunohistochemistry, providing evidence for potential clinical relevance. In cultured tubular cells, albumin induced apoptosis and increased BASP1 mRNA and protein expression at 6–48 h. Confocal microscopy localized the increased BASP1 expression in albumin-treated cells mainly to the perinuclear area. A peripheral location near the cell membrane was more conspicuous in albumin-treated apoptotic cells, where it colocalized with actin. Inhibition of BASP1 expression by a BASP1 siRNA protected from albumin-induced apoptosis. In conclusion, albumin-induced apoptosis in tubular cells is BASP1-dependent. This information may be used to design novel therapeutic approaches to slow CKD progression based on protection of tubular cells from the adverse consequences of albuminuria.
Collapse
Affiliation(s)
- M D Sanchez-Niño
- 1] Instituto de Investigacion Sanitaria IDIPAZ, Madrid, Spain [2] REDINREN, Madrid, Spain
| | - B Fernandez-Fernandez
- 1] REDINREN, Madrid, Spain [2] IIS-Fundación Jiménez Díaz-Universidad Autónoma de Madrid and Fundación Renal Iñigo Alvarez de Toledo-IRSIN, Madrid, Spain
| | - M V Perez-Gomez
- 1] REDINREN, Madrid, Spain [2] IIS-Fundación Jiménez Díaz-Universidad Autónoma de Madrid and Fundación Renal Iñigo Alvarez de Toledo-IRSIN, Madrid, Spain
| | - J Poveda
- 1] REDINREN, Madrid, Spain [2] IIS-Fundación Jiménez Díaz-Universidad Autónoma de Madrid and Fundación Renal Iñigo Alvarez de Toledo-IRSIN, Madrid, Spain
| | - A B Sanz
- 1] REDINREN, Madrid, Spain [2] IIS-Fundación Jiménez Díaz-Universidad Autónoma de Madrid and Fundación Renal Iñigo Alvarez de Toledo-IRSIN, Madrid, Spain
| | - P Cannata-Ortiz
- 1] REDINREN, Madrid, Spain [2] IIS-Fundación Jiménez Díaz-Universidad Autónoma de Madrid and Fundación Renal Iñigo Alvarez de Toledo-IRSIN, Madrid, Spain
| | - M Ruiz-Ortega
- 1] REDINREN, Madrid, Spain [2] IIS-Fundación Jiménez Díaz-Universidad Autónoma de Madrid and Fundación Renal Iñigo Alvarez de Toledo-IRSIN, Madrid, Spain
| | - J Egido
- IIS-Fundación Jiménez Díaz-Universidad Autónoma de Madrid and Fundación Renal Iñigo Alvarez de Toledo-IRSIN, Madrid, Spain
| | - R Selgas
- 1] Instituto de Investigacion Sanitaria IDIPAZ, Madrid, Spain [2] REDINREN, Madrid, Spain
| | - A Ortiz
- 1] REDINREN, Madrid, Spain [2] IIS-Fundación Jiménez Díaz-Universidad Autónoma de Madrid and Fundación Renal Iñigo Alvarez de Toledo-IRSIN, Madrid, Spain
| |
Collapse
|
8
|
Blanco-Gozalo V, Blazquez-Medela A, Garcia-Sanchez O, Quiros Y, Montero M, Martinez-Salgado C, Lopez-Hernandez F, Lopez-Novoa J, Yao L, Qing Z, Hua X, Min F, Fei M, Ning W, Cantaluppi V, Figliolini F, Delena M, Beltramo S, Medica D, Tetta C, Segoloni G, Biancone L, Camussi G, Cunha JS, Ferreira VM, Naves MA, Boim MA, Zitman-Gal T, Golan E, Green J, Pasmanik-Chor M, Bernheim J, Benchetrit S, Riera M, Clotet S, Pascual J, Soler M, Nakai K, Fujii H, Kono K, Goto S, Hirata M, Shinohara M, Fukagawa M, Nishi S, Fan Q, Du S, Jiang Y, Wang L, Fang L, Radovits T, Mozes MM, Rosivall L, Kokeny G, Aoki R, Tateoka R, Sekine F, Kikuchi K, Yamashita Y, Itoh Y, Cappuccino L, Garibotto G, D'Amato E, Villaggio B, Gianiorio F, Mij M, Viazzi F, Salvidio G, Verzola D, Piwkowska A, Rogacka D, Audzeyenka I, Kasztan M, Angielski S, Jankowski M, Gaber EW, El-Attar HA, Liu J, Zhang W, He Y, Rogacka D, Piwkowska A, Audzeyenka I, Angielski S, Jankowski M, Macsai E, Takats Z, Derzbach L, Korner A, Vasarhelyi B, Huang MS, Bo H, Liu F, Fu P, Tsotakos NE, Tsilibary EC, Drossopoulou GI, Thawho N, Farid N, Peleg A, Levy A, Nakhoul N, Lenghel AR, Borza G, Catoi C, Bondor CI, Muresan A, Kacso IM, Song JS, Song JH, Ahn SH, Choi BS, Hong YA, Kim MY, Lim JH, Yang KS, Chung S, Shin SJ, Kim HW, Chang YS, Kim YS, Park CW, Takayanagi K, Hasegawa H, Shimizu T, Ikari A, Noiri C, Iwashita T, Tayama Y, Asakura J, Anzai N, Kanozawa K, Kato H, Mitarai T, Huang M, Bo H, Liu F, Fu P, Ashour RH, Fouda AEMM, Saad MA, El-Banna FM, Moustafa FA, Fouda MI, Sanchez-Nino MD, Sanz AB, Poveda J, Saleem M, Mathieson P, Ruiz-Ortega M, Selgas R, Egido J, Ortiz A, Clotet S, Soler MJ, Rebull M, Pascual J, Riera M, Marquez E, Riera M, Pascual J, Soler MJ, Asakura J, Hasegawa H, Takayanagi K, Tayama Y, Shimizu T, Iwashita T, Okazaki S, Kogure Y, Sano T, Hatano M, Kanozawa K, Kato H, Mitarai T, Kreft E, Kowalski R, Kasztan M, Jankowski M, Szczepansk-Konkel M, Fan Q, Liu X, Yang G, Jiang Y, Wang L, Osman NA, NasrAllah MM, Kamal MM, Ahmed AI, Fekih-Mrissa N, Mrad M, Baffoun A, Sayeh A, Hmida J, Gritli N, Galchinskaya V, Topchii I, Semenovykh P, Yefimova N, Zheng D, Hu D, Li X, Peng AI, Olea-Herrero N, Arenas M, Munoz-Moreno C, Moreno-Gomez-Toledano R, Gonzalez-Santander M, Arribas I, Bosch R. Diabetes - experimental models. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Kanlaya R, Sintiprungrat K, Thongboonkerd V, Torremade N, Bindels R, Hoenderop J, Fernandez E, Dusso A, Valdivielso JM, Krueger T, Boor P, Schafer C, Westenfeld R, Brandenburg V, Schlieper G, Jahnen-Dechent W, Ketteler M, Jee W, Li X, Richards B, Floege J, Goncalves JG, Canale D, de Braganca AC, Shimizu MHM, Moyses RMA, Andrade L, Seguro AC, Volpini RA, Romoli S, Migliorini A, Anders HJ, Eskova O, Neprintseva N, Tchebotareva N, Bobkova I, Kozlovskaya L, Simic I, Tabatabaeifar M, Wlodkowski T, Denc H, Mollet G, Antignac C, Schaefer F, Ekaterina IA, Giardino L, Rastaldi MP, Van den Heuvel L, Levtchenko E, Okina C, Okamoto T, Kamata M, Murano J, Kobayashi K, Takeuchi K, Kamata F, Sakai T, Naito S, Aoyama T, Sano T, Takeuchi Y, Kamata K, Thomasova D, Bruns HA, Liapis H, Anders HJ, Iwashita T, Hasegawa H, Takayanagi K, Shimizu T, Asakura J, Okazaki S, Kogure Y, Hatano M, Hara H, Inamura M, Iwanaga M, Mitani T, Mitarai T, Savin VJ, Sharma M, Wei C, Reiser J, McCarthy ET, Sharma R, Gauchat JF, Eneman B, Freson K, Van den Heuvel L, Van Geet C, Levtchenko E, Choi DE, Jeong JY, Chang YK, Na KR, Lee KW, Shin YT, Ni HF, Chen JF, Zhang MH, Pan MM, Liu BC, Lee KW, Jeong JY, Choi DE, Chang YK, Kim SS, Na KR, Shin YT, Suzuki T, Iyoda M, Matsumoto K, Shindo-Hirai Y, Kuno Y, Wada Y, Yamamoto Y, Shibata T, Akizawa T, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Ehling J, Babickova J, Gremse F, Kiessling F, Floege J, Lammers T, Boor P, Lech M, Gunthner R, Lorenz G, Ryu M, Grobmayr R, Susanti H, Kobayashi KS, Flavell RA, Anders HJ, Rayego-Mateos S, Morgado J, Sanz AB, Eguchi S, Pato J, Keri G, Egido J, Ortiz A, Ruiz-Ortega M, Leduc M, Geerts L, Grouix B, Sarra-Bournet F, Felton A, Gervais L, Abbott S, Duceppe JS, Zacharie B, Penney C, Laurin P, Gagnon L, Detsika MG, Duann P, Lianos EA, Leong KI, Chiang CK, Yang CC, Wu CT, Chen LP, Hung KY, Liu SH, Carvalho FF, Teixeira VP, Almeida WS, Schor N, Small DM, Bennett NC, Coombes J, Johnson DW, Gobe GC, Montero N, Prada A, Riera M, Orfila M, Pascual J, Rodriguez E, Barrios C, Kokeny G, Fazekas K, Rosivall L, Mozes MM, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Hornigold N, Hughes J, Mooney A, Benardeau A, Riboulet W, Vandjour A, Jacobsen B, Apfel C, Conde-Knape K, Grouix B, Felton A, Sarra-Bournet F, Leduc M, Geerts L, Gervais L, Abbott S, Bienvenu JF, Duceppe JS, Zacharie B, Penney C, Laurin P, Gagnon L, Tanaka T, Yamaguchi J, Nangaku M, Niwa T, Bolati D, Shimizu H, Yisireyili M, Nishijima F, Brocca A, Virzi G, de Cal M, Ronco C, Priante G, Musacchio E, Valvason C, Sartori L, Piccoli A, Baggio B, Boor P, Perkuhn M, Weibrecht M, Zok S, Martin IV, Schoth F, Ostendorf T, Kuhl C, Floege J, Karabaeva A, Essaian A, Beresneva O, Parastaeva M, Kayukov I, Smirnov A, Audzeyenka I, Kasztan M, Piwkowska A, Rogacka D, Angielski S, Jankowski M, Bockmeyer CL, Kokowicz K, Agustian PA, Zell S, Wittig J, Becker JU, Nishizono R, Venkatareddy MP, Chowdhury MA, Wang SQ, Fukuda A, Wickman LT, Yang Y, Wiggins RC, Fazio MR, Donato V, Lucisano S, Cernaro V, Lupica R, Trimboli D, Montalto G, Aloisi C, Mazzeo AT, Buemi M, Gawrys O, Olszynski KH, Kuczeriszka M, Gawarecka K, Swiezewska E, Chmielewski M, Masnyk M, Rafalowska J, Kompanowska-Jezierska E, Lee WC, Chau YY, Lee LC, Chiu CH, Lee CT, Chen JB, Kim WK, Shin SJ. Experimental models of CKD. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Tsuchiya K, Shiohira S, Sugiura H, Suzuki M, Okano K, Nitta K, Kaesler N, Immendorf S, Ouyang C, Carmeliet P, Floege J, Kruger T, Schlieper G, Georgescu A, Kalucka J, Olbrich S, Baumgartl J, Hackenbeck T, Eckardt KU, Weidemann A, Chmielewski S, Olejnik A, Sikorski K, Heemann U, Wesoly J, Bluyssen H, Baumann M, Mekahli D, Decuypere JP, Missiaen L, Levtchenko E, De Smedt H, Stasi A, Castellano G, Gigante M, Intini A, Pontrelli P, Divella C, Curci C, Grandaliano G, Gesualdo L, Vizza D, Perri A, Lofaro D, Toteda P, Lupinacci S, Leone F, Gigliotti P, Papalia T, Bonofiglio R, Vatazin AV, Astakhov PV, Zulkarnaev AB, Parodi E, Verzola D, D'Amato E, Viazzi F, Gonnella A, Garneri D, Pontremoli R, Garibotto G, Chen TH, Chen CH, Chen YC, Sue YM, Cheng CY, Guiying L, Ying L, Pozzoli S, Lino M, Delli Carpini S, Ferrandi M, Zerbini G, Simonini M, Zagato L, Molinari I, Citterio L, Manunta P, Feng X, Pan X, Wang W, Chen N, Chen YX, Wang WM, Chen N, Tanaka S, Yano S, Sugimoto T, Noh H, Yu MR, Kim HJ, Woo SA, Cho YJ, Kwon SH, Jeon JS, Han DC, Shimizu H, Yisireyili M, Nishijima F, Niwa T, Koh ES, Chung S, Kim SJ, Kim SJ, Yoon HE, Park CW, Chang YS, Shin SJ, Seong EY, Rhee H, Shin MJ, Yang BY, Jung YS, Lee DW, Lee SB, Kwak IS, Kim IY, Sancho-Martinez SM, Prieto-Garcia L, Lopez-Hernandez FJ, Lopez-Novoa JM, Bae EH, Choi HS, Joo SY, Kim IJ, Kim CS, Choi JS, Ma SK, Lee J, Kim SW, Humanes B, Sonia C, Jado J, Mojena M, Lara J, Alvarez-Sala L, Tejedor A, Lazaro A, Wada Y, Iyoda M, Matsumoto K, Shindo-Hirai Y, Kuno Y, Yamamoto Y, Suzuki T, Shibata T, Akizawa T, Lee DW, Kwak IS, Lee SB, Seong EY, Faubel S, Edelstein CL, Cano Penalver JL, de Frutos Garcia S, Griera Merino M, Luengo Rodriguez A, Garcia Jerez A, Bohorquez Magro L, Medrano D, Calleros Basilio L, Rodriguez Puyol M, Prieto-Garcia L, Sancho-Martinez SM, Lopez-Hernandez FJ, Lopez-Novoa JM, Thilo F, Liu Y, Tepel M, Hsu HH, Chen KH, Hung CC, Yang CW, Endlich N, Lin JL, Pavenstadt H, Rodrigues Diez RR, Mezzano S, Ruiz-Ortega M, Rodrigues Diez R, Lavoz C, Nakayama Y, Fukami K, Yamagishi SI, Obara N, Yokoro M, Ando R, Kaida Y, Toyonaga M, Kaifu K, Takeuchi M, Ueda S, Okuda S, Daenen K, Hoylaerts MF, Bammens B, Liu J, Zhong F, Dai Q, Xu L, Wang W, Chen N, Zaravinos A, Deltas CC. Cell signalling. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Shin SJ, Rhee MY, Lim C, Lavoz C, Rodrigues-Di;ez R, Rayego-Mateos S, Benito-Martin A, Rodrigues-Diez R, Alique M, Ortiz A, Mezzano S, Ruiz-Ortega M, Axelsson J, Axelsson J, Rippe A, Sverrisson K, Rippe B, Calo L, Dal Maso L, Pagnin E, Caielli P, Calo L, Pagnin E, Dal Maso L, Caielli P, Spanos G, Spanos G, Kalaitzidis R, Karasavvidou D, Pappas K, Balafa O, Siamopoulos K, Fang TC, Lee TJF, Spanos G, Spanos G, Kalaitzidis R, Pappas E, Ermeidi E, Tatsioni A, Siamopoulos K, Blazquez-Medela A, Garcia-Sanchez O, Quiros Y, Lopez-Hernandez FJ, Lopez-Novoa JM, Martinez-Salgado C, Wu HY, Peng YS, Hung KY, Tsai TJ, Tu YK, Chien KL, Larsen T, Mose FH, Hansen AB, Pedersen EB, Quiroz Y, Rivero M, Yaguas K, Rodriguez-Iturbe B, Xydakis D, Sfakianaki M, Petra C, Maragaki E, Antonaki E, Krasoudaki E, Kostakis K, Stylianou K, Papadogiannakis A, Sagliker Y, Paylar N, Heidland A, Keck A, Erek R, Kolasin P, S Ozkaynak P, Sagliker HS, Gokcay I, Ritz E, Koleganova N, Gross-Weissmann ML, Piecha G, Reinecke N, Marquez Cunha T, M . S. Higa E, Pfeferman Heilberg I, Neder JA, Nishiura JL, Silva Almeida W, Schor N, Tapia E, Sanchez-Lozada LG, Cristobal M, Soto V, Garci;a-Arroyo F, Monroy-Sanchez F, Madero M, Johnson R, Kim SM, Yang SH, Kim YS, Karanovic S, Fistrek M, Kos J, Pecin I, Premuzic V, Abramovic M, Matijevic V, Cvoriscec D, Cvitkovic A, Knezevic M, Bitunjac M, Laganovic M, Jelakovic B, Liu F, Wu M, Fu P, Klok Matthesen S, Klok Matthesen S, Larsen T, Guldager Lauridsen T, Vase H, Gjorup Holland P, Nykjaer KM, Nielsen S, Bjerregaard Pedersen E, Blazquez-Medela A, Lopez-Hernandez FJ, Garcia-Sanchez O, Quiros Y, Montero MJ, Lopez-Novoa JM, Martinez-Salgado C, Vink E, Willemien V, Michiel V, Wilko S, Evert-Jan V, Blankestijn P, Zerbi S, Pedrini LA, Zbroch E, Zbroch E, Malyszko J, Malyszko J, Koc-Zorawska E, Mysliwiec M, Quelhas-Santos J, Quelhas-Santos J, Serrao P, Soares-Silva I, Tang L, Sampaio-Maia B, Desir G, Pestana M, Elsurer R, Demir T, Celik G, Yavas M, Yavas O, Murphy M, Jacquillet G, Unwin RJ, Chichger H, Shirley DG, Caraba A, Andreea M, Corina S, Ioan R, Nowicki M, Bobik M, Pawelec A, Lacisz J, Zapala A, Bryc K, Esposito C, Scaramuzzi ML, Manini A, Torreggiani M, Beneventi F, Spinillo A, Grosjean F, Fasoli G, Dal Canton A, Christos C, Christos C, Bernhard M.W. S, Martin N, Jan K, Claus M, Leyla R, Jan B, Ulrich K, Hermann H, Menne J, Pavicevic M, Pavicevic M, Markovic S, Igrutinovic Z. Hypertension. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
12
|
Beck FX, Kuper C, Neuhofer W, Rodrigues-Diez R, Stark Aroeira LG, Jimenez JA, Rodrigues-Diez R, Rayego-Mateos S, Bajo Rubio A, Ortiz A, Egido J, Lopez-Cabrera M, Selgas R, Ruiz-Ortega M, Pedro Ventura A, Olivia S, Teixeira L, Joana V, Francisco F, Maria Joao C, Antonio C, Rodrigues AS, Vychytil A, Kerschbaum J, Lhotta K, Prischl F, Wiesholzer M, Kopriva-Altfahrt G, Machold-Fabrizii V, Schwarz C, Balcke P, Oberbauer R, Kramar R, Konig P, Rudnicki M, Habib M, Betjes M, Korte M, Vidal E, Edefonti A, Chimenz R, Gianoglio B, Leozappa G, Maringhini S, Mencarelli F, Pecoraro C, Puteo F, Testa S, Cannavo R, Verrina E. Peritoneal dialysis. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Rayego-Mateos S, Rodrigues-Diez R, Rodrigues-Diez RR, Lavoz-Barria C, Alique M, Mas S, Pato J, Keri G, Egido J, Ortiz A, Ruiz-Ortega M, Ying L, Tepel M, Frank E, Florian T, Gregor T, Boye J, Maik G, Teng B, Gu C, Haller H, Sever S, Schiffer M, Worthmann K, Leitges M, Dittrich-Breiholz O, Kracht M, Haller H, Schiffer M, Peired A, Angelotti ML, Ronconi E, Lazzeri E, Sisti A, Lasagni L, Romagnani P. Mechanisms and targets of glomerular damage. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Yi Chun DX, Alexandre H, Edith B, Nacera O, Julie P, Chantal J, Eric R, Zhang X, Jin Y, Miravete M, Dissard R, Klein J, Gonzalez J, Caubet C, Pecher C, Pipy B, Bascands JL, Mercier-Bonin M, Schanstra J, Buffin-Meyer B, Claire R, Rigothier C, Richard D, Sebastien L, Moin S, Chantal B, Christian C, Jean R, Migliori M, Migliori M, Cantaluppi V, Mannari C, Medica D, Giovannini L, Panichi V, Goldwich A, Alexander S, Andre G, Amann K, Migliorini A, Sagrinati C, Angelotti ML, Mulay SR, Ronconi E, Peired A, Romagnani P, Anders HJ, Chiang WC, Lai CF, Peng WH, Wu CF, Chang FC, Chen YT, Lin SL, Chen YM, Wu KD, Lu KS, Tsai TJ, Virgine O, Qing Feng F, Zhang SY, Dominique D, Vincent A, Marina C, Philippe L, Georges G, Pawlak A, Sahali D, Matsumoto S, Kiyomoto H, Ichimura A, Dan T, Nakamichi T, Tsujita T, Akahori K, Ito S, Miyata T, Xie S, Zhang B, Shi W, Yang Y, Nagasu H, Satoh M, Kidokoro K, Nishi Y, Ihoriya C, Kadoya H, Sasaki T, Kashihara N, Wu CF, Chang FC, Chen YT, Chou YH, Duffield J, Lin SL, Rocca C, Rocca C, Gregorini M, Corradetti V, Valsania T, Bedino G, Bosio F, Pattonieri EF, Esposito P, Sepe V, Libetta C, Rampino T, Dal Canton A, Bedino G, Gregorini M, Corradetti V, Rocca C, Pattonieri EF, Valsania T, Bosio F, Esposito P, Sepe V, Libetta C, Rampino T, Dal Canton A, Omori H, Kawada N, Inoue K, Ueda Y, Yamamoto R, Matsui I, Kaimori J, Takabatake Y, Moriyama T, Isaka Y, Rakugi H, Wasilewska A, Taranta-Janusz K, Deebek W, Kuroczycka-Saniutycz E, Lee AS, Lee AS, Lee JE, Jung YJ, Kang KP, Lee S, Kim W, Arfian N, Emoto N, Yagi K, Nakayama K, Hartopo AB, Nugrahaningsih DA, Yanagisawa M, Hirata KI, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Oujo B, Munoz-Felix JM, Arevalo M, Bernabeu C, Perez-Barriocanal F, Lopez-Novoa JM, Jesper K, Nathalie V, Pierre G, Yi Chun DX, Alexandre H, Eric R, Iyoda M, Shibata T, Matsumoto K, Shindo-Hirai Y, Kuno Y, Wada Y, Akizawa T, Schwartz I, Schwartz D, Prot Bertoye C, Prot Bertoye C, Terryn S, Claver J, Beghdadi WB, Monteiro R, Blank U, Devuyst O, Daugas E, Van Beneden K, Geers C, Pauwels M, Mannaerts I, Van den Branden C, Van Grunsven LA, Seckin I, Pekpak M, Uzunalan M, Uruluer B, Kokturk S, Ozturk Z, Sonmez H, Yaprak E, Furuno Y, Tsutsui M, Morishita T, Shimokawa H, Otsuji Y, Yanagihara N, Kabashima N, Ryota S, Kanegae K, Miyamoto T, Nakamata J, Ishimatsu N, Tamura M, Nakagawa T, Nakagawa T, Ichikawa K, Miyamoto M, Takabayashi D, Yamazaki H, Kakeshita K, Koike T, Kagitani S, Tomoda F, Hamashima T, Ishii Y, Inoue H, Sasahara M, El Machhour F, Kerroch M, Mesnard L, Chatziantoniou C, Dussaule JC, Inui K, Sasai F, Maruta Y, Nishiwaki H, Kawashima E, Inoue Y, Yoshimura A, Matsumoto K, Matsumoto K, Iyoda M, Shibata T, Wada Y, Shindo-Hirai Y, Kuno Y, Akizawa T, Musacchio E, Priante G, Valvason C, Sartori L, Baggio B, Kim JH, Gross O, Diana R, Gry DH, Asimal B, Johanna T, Imke SE, Lydia W, Gerhard-Anton M, Hassan D, Cano JL, Griera M, Olmos G, Martin P, Cortes MA, Lopez-Ongil S, Rodriguez-Puyol D, DE Frutos S, Gonzalez M, DE Frutos S, Cano JL, Luengo A, Martin P, Rodriguez-Puyol M, Calleros L, Lupica R, Lacquaniti A, Donato V, Maggio R, Mastroeni C, Lucisano S, Cernaro V, Fazio MR, Quartarone A, Buemi M, Kacik M, Goedicke S, Eggert H, Hoyer JD, Wurm S, Wurm S, Steege A, Banas M, Kurtz A, Banas B, Lasagni L, Lazzeri E, Peired A, Angelotti ML, Ronconi E, Romoli S, Romagnani P, Schaefer I, Teng B, Worthmann K, Haller H, Schiffer M, Prattichizzo C, Netti GS, Rocchetti MT, Cormio L, Carrieri G, Stallone G, Grandaliano G, Ranieri E, Gesualdo L, Kucher A, Smirnov A, Parastayeva M, Beresneva O, Kayukov I, Zubina I, Ivanova G, Abed A, Schlekenbach L, Foglia B, Chatziantoniou C, Kwak B, Chadjichristos C, Queisser N, Schupp N, Brand S, Himer L, Himer L, Szebeni B, Sziksz E, Saijo S, Kis E, Prokai A, Banki NF, Fekete A, Tulassay T, Vannay A, Hegner B, Schaub T, Lange C, Dragun D, Klinkhammer BM, Rafael K, Monika M, Anna M, Van Roeyen C, Boor P, Eva Bettina B, Simon O, Esther S, Floege J, Kunter U, Hegner B, Janke D, Schaub T, Lange C, Jankowski J, Dragun D, Hayashi M, Takamatsu I, Horimai C, Yoshida T, Seno DI Marco G, Koenig M, Stock C, Reiermann S, Amler S, Koehler G, Fobker M, Buck F, Pavenstaedt H, Lang D, Brand M, Plotnikov E, Morosanova M, Pevzner I, Zorova L, Pulkova N, Zorov D, Wornle M, Ribeiro A, Belling F, Merkle M, Nakazawa D, Nishio S, Shibasaki S, Tomaru U, Akihiro I, Kobayashi I, Imanishi Y, Kurajoh M, Nagata Y, Yamagata M, Emoto M, Michigami T, Ishimura E, Inaba M, Nishi Y, Satoh M, Sasaki T, Kashihara N, Wu CC, Lu KC, Chen JS, Chu P, Lin YF, Eller K, Schroll A, Banas M, Kirsch A, Huber J, Weiss G, Theurl I, Rosenkranz AR, Zawada A, Rogacev K, Achenbach M, Fliser D, Held G, Heine GH, Miyamoto Y, Iwao Y, Watanabe H, Kadowaki D, Ishima Y, Chuang VTG, Sato K, Otagiri M, Maruyama T, Ueda Y, Iwatani H, Isaka Y, Watanabe H, Honda D, Miyamoto Y, Noguchi T, Kadowaki D, Ishima Y, Tanaka M, Tanaka H, Fukagawa M, Otagiri M, Maruyama T, Wornle M, Ribeiro A, Pircher J, Koppel S, Mannell H, Krotz F, Merkle M, Virzi GM, Bolin C, Cruz D, Scalzotto E, De Cal M, Vescovo G, Ronco C, Virzi GM, Bolin C, Cruz D, Scalzotto E, De Cal M, Vescovo G, Ronco C, Grobmayr R, Lech M, Ryu M, Anders HJ, Aoshima Y, Mizobuchi M, Ogata H, Kumata C, Nakazawa A, Kondo F, Ono N, Koiwa F, Kinugasa E, Akizawa T, Freisinger W, Lale N, Lampert A, Ditting T, Heinlein S, Schmieder RE, Veelken R, Nave H, Perthel R, Suntharalingam M, Bode-Boger S, Beutel G, Kielstein J, Rodrigues-Diez R, Rodrigues-Diez R, Rayego-Mateos S, Lavoz C, Stark Aroeira LG, Orejudo M, Alique M, Ortiz A, Egido J, Ruiz-Ortega M, Oskar W, Rusan C, Schaub T, Hegner B, Dragun D, Padberg JS, Wiesinger A, Brand M, Seno DI Marco G, Reuter S, Grabner A, Kentrup D, Lukasz A, Oberleithner H, Pavenstadt H, Kumpers P, Eberhardt HU, Skerka C, Chen Q, Hallstroem T, Hartmann A, Kemper MJ, Zipfel PF, N'gome-Sendeyo K, Fan QF, Zhang SY, Pawlak A, Sahali D, Wornle M, Ribeiro A, Merkle M, Toblli J, Toblli J, Cao G, Giani JF, Dominici FP, Kim JS, Yang JW, Kim MK, Han BG, Choi SO. Experimental pathology. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Lopez-Parra V, Mallavia B, Oguiza A, Recio C, Egido J, Gomez-Guerrero C, Ito M, Nishio S, Koike T, Takayanagi K, Hasegawa H, Shimizu T, Asakura J, Iwashita T, Tayama Y, Hara H, Inamura M, Kanozawa K, Kato H, Mitarai T, Sanchez-Nino MD, Sanchez-Lopez E, Sanz AB, Ruiz-Ortega M, Saleem MA, Mathieson PW, Mezzano S, Egido J, Ortiz A, Liu L, Hu X, Cai GY, Lv Y, Zhuo L, Gao JJ, Cui SY, Feng Z, Fu B, Chen XM, Zaladek Gil F, Costa MC, Hirata AE, Camara NO, Chen JS, Chang LC, Shieh YS, Wu CC, Zhang L, Gu Y, Lin S, Buraczynska M, Zukowski P, Kuczmaszewska A, Ksiazek A, Kimachi M, Ito M, Sato A, Nakagaki T, Nakazawa D, Ishikawa Y, Shibasaki S, Nishio S, Koike T, Ahn EM, Choi JY, Shin JI, Ha TS, Buraczynska M, Zukowski P, Mozul S, Dragan M, Lumi Z, Liu J, Xiufen Z, Jun Q, Changying X, Zitman-Gal T, Green J, Bernheim J, Benchetrit S, Watanabe M, Nakashima H, Abe Y, Ito K, Sato T, Saito T, Riera M, Marquez E, Rigol J, Roca H, Pascual J, Soler MJ, Aizawa K, Hirata M, Moriguchi Y, Iehara N, Terada M, Matsubara T, Araki M, Torikoshi K, Doi T, Fukatsu A. Diabetes - Basic research. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
16
|
McCabe K, Shobeiri N, Beseau D, Adams M, Holden R, Shobeiri N, Adams M, Holden R, Maio T, McCabe K, Laverty K, Beseau D, Pang J, Jozefacki A, Shobeiri N, Holden R, Adams M, Salem S, Jankowski V, Passlick-Deetjen J, Peter M, Zidek W, Jankowski J, Riser B, Barreto F, Valaitis P, Cook C, White J, Drueke T, Holmes C, Massy Z, Mizobuchi M, Ogata H, Kumata C, Nakazawa A, Koiwa F, Kinugasa E, Akizawa T, Lopez I, Aguilera-Tejero E, Guerrero F, Pineda C, Raya AI, Peralta A, Rodriguez M, Ciceri P, Volpi E, Brenna I, Brancaccio D, Cozzolino M, Bozic M, deRoij J, Parisi E, Ruiz-Ortega M, Fernandez E, Valdivielso JM, Lee CT, Ng HY, Tsai YC, Yang YK, Niwa T, Adijiang A, Shimizu H, Nishijima F, Okamoto T, Kamata K, Naito S, Aoyama T, Tazaki H, Yamanaka N, Koenigshausen E, Ohlsson S, Woznowski M, Quack I, Potthoff SA, Rump LC, Sellin L, Maquigussa E, Pereira L, Arnoni C, Boim M, Lee KW, Jeong JY, Jang WI, Chung S, Choi DE, Na KR, Shin YT, Slabiak-Blaz N, Adamczak M, Ritz E, Wiecek A, Uz E, Uz B, Sahin Balcik O, Kaya A, Akdeniz D, Bavbek Ruzgaresen N, Uz E, Turgut FH, Bayrak R, Carlioglu A, Akcay A, Galichon P, Vittoz N, Cornaire E, Baugey E, Vandermeersch S, Verpont MC, Mesnard L, Xu-Dubois YC, Hertig A, Rondeau E, Kokeny G, Fekeshazy O, Fang L, Rosivall L, Mozes MM, Duggan K, Hodge G, Ha H, Chen J, Lee L, Tay C, Macdonald G, Wang PHM, Tamouza H, Chemouny J, Monsinjon E, Tiwari M, Vende F, Vrtovsnik F, Camara NO, Benhamou M, Monteiro RC, Moura IC, Rigothier C, Saleem M, Ripoche J, Mathieson P, Combe C, Welsh G, Duwel A, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Koutroutsos K, Kassimatis T, Nomikos A, Giannopoulou I, Papadakis J, Nakopoulou L, Nakamichi T, Mori T, Sato T, Sato H, Ito S, Neudecker S, Heilmann M, Kramer P, Wolf I, Sticht C, Schock-Kusch D, Gubhaju L, Kriz W, Bertram JF, Schad LR, Gretz N, Munoz-Felix JM, Fuentes-Calvo I, Lopez-Novoa JM, Martinez-Salgado C, Kimura T, Takabatake Y, Takahashi A, Kaimori JY, Matsui I, Namba T, Kitamura H, Niimura F, Matsusaka T, Soga T, Rakugi H, Isaka Y, Shin SJ, Kim KS, Kim WK, Rampanelli E, Teske G, Leemans J, Florquin S, Small D, Bennett N, Roy S, Gobe G, Blazquez-Medela AM, Garcia-Sanchez O, Lopez-Hernandez FJ, Lopez-Novoa JM, Martinez-Salgado C, Deibel A, Cheng J, Warner G, Knudsen B, Gray C, Lien K, Juskewitch J, Grande J, Wang N, Wang X, Zeng M, Sun B, Xing C, Zhao X, Xiong M, Yang J, Cao K, Priante G, Musacchio E, Sartori L, Valvason C, Baggio B, Pitlovanciv EDON, Reis LA, Pessoa EA, Teixeira L, Borges FT, Simoes MJ, Schor N, Munoz-Felix JM, Duwel A, Lopez-Novoa JM, Martinez-Salgado C, Doustar Y, Mohajeri D, Smirnov AV, Kucher AG, Ivanova GT, Berseneva ON, Parastaeva MM, Zarajsky MI, Saburova IJ, Kaukov IG, Koppe L, Fouque D, Dugenet Y, Soulage C, Wan J, Yang X, Cui J, Zou Z. Experimental pathology. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Ortiz A, Sanchez-Niño MD, Izquierdo MC, Blanco-Colio LM, Selgas R, Ruiz-Ortega M, Egido J, Sanz AB. TWEAK and the kidney: the dual role of a multifunctional cytokine. Adv Exp Med Biol 2011; 691:323-35. [PMID: 21153336 DOI: 10.1007/978-1-4419-6612-4_33] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Ana Ortiz
- Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Fundación Renal Iñigo Alvarez de Toledo, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Goncalves S, Fernandez-Sanchez R, Sanchez-Nino M, Tejedor A, Neria F, Egido J, Ruiz-Ortega M, Ortiz A. Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury. Curr Med Chem 2010; 17:974-86. [DOI: 10.2174/092986710790820642] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2009] [Accepted: 01/23/2010] [Indexed: 11/22/2022]
|
19
|
Carvajal G, Droguett A, Burgos ME, Aros C, Ardiles L, Flores C, Carpio D, Ruiz-Ortega M, Egido J, Mezzano S. Gremlin: a novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy. Transplant Proc 2008; 40:734-9. [PMID: 18455002 DOI: 10.1016/j.transproceed.2008.02.064] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Chronic allograft nephropathy (CAN) is the most frequent cause of chronic dysfunction and late loss of renal allografts. Epithelial mesenchymal transition (EMT) has been identified as responsible for the presence of activated interstitial fibroblasts (myofibroblasts) and transforming growth factor beta (TGF-beta)/Smad is the key signaling mediator. It has been proposed that the bone morphogenetic protein 7 (BMP-7) antagonist, Gremlin, could participate in EMT, as a downstream mediator of TGF-beta. METHODS We evaluated 33 renal allograft biopsies, 16 of which showed CAN, versus 17 controls. By in situ hybridization we studied the expression of TGF-beta and Gremlin mRNA. Gremlin, BMP-7, E-cadherin, and alpha-smooth muscle actin (alpha-SMA) proteins were evaluated by immunohistochemistry and Smad3 activation by Southwestern. In cultured human tubuloepithelial cells (HK2 cell line), Gremlin induction by TGF-beta was studied by confocal microscopy. RESULTS Among renal biopsies of transplanted patients with CAN, we detected up-regulation of TGF-beta in colocalization with Gremlin (RNA and protein), mainly in areas of tubulointerstitial fibrosis. In the same tubules, we observed decreased expression of E-cadherin and induction of vimentin and alpha-SMA. BMP-7 was significantly decreased in the CAN biopsies. In addition, HK2 stimulated with TGF-beta (1 ng/mL) induced Gremlin production at 72 hours. CONCLUSION We postulated that Gremlin is a downstream mediator of TGF-beta, suggesting a role for Gremlin in EMT observed in CAN.
Collapse
Affiliation(s)
- G Carvajal
- Division of Nephrology, School of Medicine, Universidad Austral, Valdivia, Chile
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Rámila D, Ardura J, Esteban V, Ortega A, Ruiz-Ortega M, Bosch R, Esbrit P. Parathyroid hormone-related protein promotes inflammation in the kidney with an obstructed ureter. Kidney Int 2008; 73:835-47. [DOI: 10.1038/sj.ki.5002775] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
21
|
Sanz AB, Sánchez-Nino MDS, Izquierdo MC, Moreno JA, Ucero AC, Benito-Martín A, Santamaría B, Burgos C, Egido J, Ramos A, Berzal S, Coto E, Ruiz-Ortega M, Blanco-Colio LM, Ortiz A. [TWEAK, the facilitator of acute kidney injury]. Nefrologia 2008; 28:587-592. [PMID: 19016630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Affiliation(s)
- A B Sanz
- Fundación Jiménez Diaz, Universidad Autónoma de Madrid, España
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
González-Mateo GT, Loureiro-Alvarez J, Rayego-Mateos S, Ruiz-Ortega M, López-Cabrera M, Selgas R, Aroeira LS. [Animal models of peritoneal dialysis: relevance, difficulties, and future]. Nefrologia 2008; 28 Suppl 6:17-22. [PMID: 18957007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
The studies performed with human peritoneal biopsies of peritoneal dialysis -patients have demonstrated that exposure to peritoneal dialysis fluid induce peritoneal deterioration. The main alterations of peritoneal membrane are fibrosis and angiogenesis that ends with the failure of the ultrafiltration capacity of the peritoneal membrane. These studies are descriptivist and scarcely help to investigate the mechanisms and stages involved on the process. Therefore, it is necessary to supply the deficiencies presented by the studies with patients. The experimental models have strongly contributed to the knowledge of the pathologic process that is induced by the continuous exposition of the peritoneal membrane to the dialysis fluids. Most of the peritoneal dialysis studies use the rat as the experimental animal. Due to the difficulty of working with small animals, few studies have been done in mice. However, models in mice offers great advantages, as long as they allow us to employ different strains and genetically modified animals. We have recently developed an experimental model in mouse of exposure of the peritoneal membrane to dialysis fluids, which resembles the process of peritoneal damage that take place during peritoneal dialysis treatment in human patients.
Collapse
Affiliation(s)
- G T González-Mateo
- Unidad de Investigación. Hospital Universitario La PazPaseo de la Castellana, 26128046 Madrid. España
| | | | | | | | | | | | | |
Collapse
|
23
|
De las Heras N, Ruiz-Ortega M, Miana M, Rupérez M, Sanz-Rosa D, Aragoncillo P. Interacciones entre la aldosterona y el factor de crecimiento del tejido conjuntivo en la lesión vascular y renal de ratas espontáneamente hipertensas. Hipertensión y Riesgo Vascular 2007. [DOI: 10.1016/s1889-1837(07)71867-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Egido J, Ruiz-Ortega M, Muñoz-García B, Martín-Ventura JL, Blanco-Colio LM. [Vasoprotective effects of statins and angiotensin II blockers in atherothrombosis]. Nefrologia 2005; 25 Suppl 2:117-28. [PMID: 16050414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023] Open
Abstract
Cardiovascular disease, including atherothrombosis, is the most frequent cause of mortality in the Western World. In the last years, major advances have been made in the pathogenesis of this disease. Currently, the drugs most widely used are the inhibitors of the HMG-CoA reductase (statins) and the antihypertensive drugs, mainly angiotensin II blockers. The first group has been shown to be effective on cardiovascular disease due to atherothrombosis, and the second group on hypertensive disease. Nevertheless, recent data suggest that these two situations can improve with the concomitant use of both drugs.
Collapse
Affiliation(s)
- J Egido
- Laboratorio de Patología Vascular y Nefrología Experimental, Fundación Jiménez Díaz, Universidad Autónoma de Madrid.
| | | | | | | | | |
Collapse
|
25
|
Sánchez-López E, Ruperez M, Rodriguez-Vita J, Esteban V, López A, Egido J, Ruiz-Ortega M. INTERLEUKIN-1BETA INHIBITS CONNECTIVE TISSUE GROWTH FACTOR AND FIBRONECTIN PRODUCTION CAUSED BY ANGIOTENSIN II IN MESANGIAL CELLS. J Hypertens 2004. [DOI: 10.1097/00004872-200406002-00140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Alcázar R, Ruiz-Ortega M, Egido J. [Angiotensin II : a key peptide in vascular and renal failure]. Nefrologia 2003; 23 Suppl 4:27-35. [PMID: 14626811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023] Open
Affiliation(s)
- R Alcázar
- Servicio de Nefrología, Hospital Virgen de Alarcos, Ciudad Real
| | | | | |
Collapse
|
27
|
Ruiz-Ortega M, Lorenzo O, Rupérez M, Esteban V, Mezzano S, Egido J. Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. Contrib Nephrol 2002:123-37. [PMID: 11705278 DOI: 10.1159/000060153] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Affiliation(s)
- M Ruiz-Ortega
- Laboratory of Vascular and Renal Pathology, Fundación Jiménez Díaz, Universidad Autónoma Madrid, Spain
| | | | | | | | | | | |
Collapse
|
28
|
Ruiz-Ortega M, Lorenzo O, Rupérez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 2001; 38:1382-7. [PMID: 11751722 DOI: 10.1161/hy1201.100589] [Citation(s) in RCA: 213] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The renin-angiotensin system (RAS) has emerged as one of the essential links in the pathophysiology of vascular disease. Angiotensin (Ang) II, the main peptide of the RAS, was considered as a vasoactive hormone, but in the past years, this view has been modified to a growth factor that regulates cell proliferation/apoptosis and fibrosis. Recently, this view has been enlarged with a novel concept: Ang II participates in the inflammatory response, acting as a proinflammatory mediator. In resident vascular cells, Ang II produces chemokines, cytokines, and adhesion molecules, which contribute to the migration of inflammatory cells into the tissue injury. Ang II is also a chemotactic and mitogenic factor for mononuclear cells. The molecular mechanisms of Ang II-induced vascular damage are mediated by the activation of transcription factors, redox signaling systems, and production of endogenous growth factors. In addition, other components of the RAS could also be involved in the pathogenesis of cardiovascular diseases. The Ang II degradation product Ang III shares some of its properties with Ang II, including chemotaxis and production of growth factors and chemokines. All these data clearly demonstrate that Ang II is a true cytokine, show the complexity of the RAS in pathological processes, and provide some mechanistic responses of the beneficial effects of the treatment with RAS blockers in cardiovascular diseases.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Laboratory of Vascular and Renal Pathology, Fundación Jiménez Díaz, Universidad Autónoma Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
Angiotensin (Ang) II, the main peptide of the renin angiotensin system (RAS), is a renal growth factor, inducing hyperplasia/hypertrophy depending on the cell type. This vasoactive peptide activates mesangial and tubular cells and interstitial fibroblasts, increasing the expression and synthesis of extracellular matrix proteins. Some of these effects seem to be mediated by the release of other growth factors, such as TGF-beta. In experimental models of kidney damage, renal RAS activation, cell proliferation, and upregulation of growth factors and matrix production were described. In some of these models, blockade of Ang II actions by ACE inhibitors and angiotensin type 1 (AT(1)) antagonists prevents proteinuria, gene expression upregulation, and fibrosis, as well as inflammatory cell infiltration. Interestingly, Ang II could also be involved in the fibrotic process because of its behavior as a proinflammatory cytokine, participating in various steps of the inflammatory response: Ang II (1) activates mononuclear cells and (2) increases proinflammatory mediators (cytokines, chemokines, adhesion molecules, nuclear factor kappaB). Finally, Ang II also regulates matrix degradation. These data show that drugs controlling this complex vasoactive peptide are probably one of the best ways of avoiding fibrosis in progressive renal diseases.
Collapse
Affiliation(s)
- S A Mezzano
- Division of Nephrology School of Medicine, Universidad Austral, Valdivia, Chile
| | | | | |
Collapse
|
30
|
Ruiz-Ortega M, Lorenzo O, Rupérez M, Suzuki Y, Egido J. Angiotensin II activates nuclear transcription factor‐κB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. Nephrol Dial Transplant 2001; 16 Suppl 1:27-33. [PMID: 11369817 DOI: 10.1093/ndt/16.suppl_1.27] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Nuclear factor-kappaB (NF-kappaB) regulates many genes involved in vascular physiopathology. Angiotensin II (Ang II) participates in the pathogenesis of several cardiovascular diseases. In a model of atherosclerosis, we have noted NF-kappaB activation in the neointimia lesion that was decreased by angiotensin-converting enzyme (ACE) inhibitors. However, the potential direct effect of Ang II in the vascular activation of NF-kappaB has not been completely elucidated. METHODS We first investigated whether Ang II elicited in vivo activation of NF-kappaB in large vessels of normal rats by systemic infusion of Ang II (50 ng/kg/min, s.c.) into rats for 72 h. In order to investigate the receptor involved in this process, we also studied the direct effect of Ang II on cultured vascular smooth muscle cells (VSMCs) from wild-type and AT1 knockout mice. RESULTS Ang II-infused rats showed activated NF-kappaB in the endothelial and vascular smooth muscle cells of the aorta (southwestern histochemistry). In cultured VSMCs from wild-type mice, Ang II increased NF-kappaB activity that was partially inhibited by AT1 (losartan) and AT2 (PD123319) antagonists. In VSMC from AT1 knockout mice, Ang II also activated NF-kappaB. CONCLUSIONS These data show that Ang II via AT1 and AT2 activates NF-kappaB in vascular cells both in vivo and in vitro, and suggest a potential involvement of the AT2 receptor in the pathogenesis of vascular diseases, including hypertension and atherosclerosis.
Collapse
MESH Headings
- Angiotensin II/pharmacology
- Angiotensin Receptor Antagonists
- Animals
- Aorta/drug effects
- Aorta/metabolism
- Base Sequence
- Binding Sites
- Cells, Cultured
- Consensus Sequence
- Endothelium, Vascular/drug effects
- Endothelium, Vascular/metabolism
- Gene Expression Regulation/drug effects
- Gene Expression Regulation/physiology
- Imidazoles/pharmacology
- Losartan/pharmacology
- Mice
- Mice, Knockout
- Models, Biological
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- NF-kappa B/drug effects
- NF-kappa B/metabolism
- Pyridines/pharmacology
- Rats
- Receptor, Angiotensin, Type 1
- Receptor, Angiotensin, Type 2
- Receptors, Angiotensin/deficiency
- Receptors, Angiotensin/genetics
- Receptors, Angiotensin/physiology
- Transcription Factors/metabolism
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Laboratory of Vascular and Renal Pathology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | | | | | |
Collapse
|
31
|
Ruiz-Ortega M, Lorenzo O, Rupérez M, Blanco J, Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol 2001; 158:1743-56. [PMID: 11337372 PMCID: PMC1891960 DOI: 10.1016/s0002-9440(10)64130-2] [Citation(s) in RCA: 151] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Recent studies have pointed out the implication of angiotensin II (Ang II) in various pathological settings. However, the molecular mechanisms and the AngII receptor (AT) subtypes involved are not fully identified. We investigated whether AngII elicited the in vivo activation of nuclear transcription factors that play important roles in the pathogenesis of renal and vascular injury. Systemic infusion of Ang II into normal rats increased renal nuclear factor (NF)-kappaB and AP-1 binding activity that was associated with inflammatory cell infiltration and tubular damage. Interestingly, infiltrating cells presented activated NF-kappaB complexes, suggesting the involvement of AngII in inflammatory cell activation. When rats were treated with AT(1) or AT(2) receptor antagonists different responses were observed. The AT(1) antagonist diminished NF-kappaB activity in glomerular and tubular cells and abolished AP-1 in renal cells, improved tubular damage and normalized the arterial blood pressure. The AT(2) antagonist diminished mononuclear cell infiltration and NF-kappaB activity in glomerular and inflammatory cells, without any effect on AP-1 and blood pressure. These data suggest that AT(1) mainly mediates tubular injury via AP-1/NF-kappaB, whereas AT(2) receptor participates in the inflammatory cell infiltration in the kidney by NF-kappaB. Our results provide novel information on AngII receptor signaling and support the recent view of Ang II as a proinflammatory modulator.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Laboratory of Vascular and Renal Pathology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.
| | | | | | | | | |
Collapse
|
32
|
Abstract
Many experimental data have suggested that the renin-angiotensin system participates in immune and inflammatory responses. Angiotensin II is involved in several steps of the inflammatory process: mononuclear cells respond to angiotensin II stimulation (cell proliferation and chemotaxis); angiotensin II regulates the recruitment of proinflammatory cells into the site of injury (mediated by the expression of vascular permeability factors, adhesion molecules and chemokines by resident cells); inflammatory cells can produce angiotensin II, and might therefore contribute to the perpetuation of tissue damage. In this review, we summarize the proinflammatory properties of angiotensin II, to demonstrate the novel role of this vasoactive peptide as a true cytokine. We will show the information obtained as a result of the pharmacological blockade of the renin angiotensin system, which has demonstrated that this system is involved in immune and inflammatory diseases. In this aspect, we discuss the molecular mechanism of angiotensin II-induced tissue damage, as well as its contribution to the pathogenesis of several diseases, including atherosclerosis, hypertension and renal damage, showing that angiotensin II plays an active role in the inflammatory response of these diseases.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Laboratory of Vascular and Renal Pathology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | | | | | |
Collapse
|
33
|
Suzuki Y, Ruiz-Ortega M, Egido J. Angiotensin II: a double-edged sword in inflammation. J Nephrol 2000; 13 Suppl 3:S101-10. [PMID: 11132026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Clinical and basic research has increased our knowledge of the actions of the vasoactive hormone angiotensin II (Ang II), showing that it has multifunctional properties beyond its hemodynamic effects. It is commonly accepted that Ang II is a growth factor that participates in pathological settings, including renal diseases. However, a new aspect of this peptide is coming into focus: its potential role as a proinflammatory modulator. In this review, we summarize the apparently confusing information about the properties of Ang II and discuss its relations to the inflammatory process, as well as the potential mechanisms mediated by activation of nuclear transcription factors. Ang II seems to participate in the key events of the inflammatory response: First, it increases vascular permeability (via prostaglandins and vascular endothelial cell growth factor/vascular permeability factor) thus initiating the inflammatory process. Second, it participates in the recruitment of infiltrating cells into the tissues through direct activation of the inflammatory cells or by regulation of the expression of adhesion molecules and chemokines by resident cells. Finally, Ang II may contribute to tissue repair by regulation of cell growth and matrix synthesis. The renin-angiotensin system (RAS) thus appears to serve as a vascular inflammatory regulator and may even participate in immunologically-induced inflammation. However, more often activation of the RAS has an undesirable outcome, such as overhealing, because the inflammatory repair response itself involves a functionally imperfect system.
Collapse
Affiliation(s)
- Y Suzuki
- Renal and Vascular Research Laboratory, Fundación Jiménez Díaz, Madrid, Spain
| | | | | |
Collapse
|
34
|
Ruiz-Ortega M, Lorenzo O, Rupérez M, König S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000; 86:1266-72. [PMID: 10864918 DOI: 10.1161/01.res.86.12.1266] [Citation(s) in RCA: 219] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Nuclear factor-kappaB (NF-kappaB) regulates many genes involved in vascular physiopathology. We have previously observed in vivo NF-kappaB activation in injured vessels that diminished by angiotensin-converting enzyme inhibition. In the present work, we investigated the effect of angiotensin II (Ang II) on NF-kappaB activity in rat vascular smooth muscle cells, evaluating the molecular mechanisms and the specific receptor subtype involved. Ang II increased NF-kappaB DNA binding (5-fold, 10(-)(9) mol/L at 1 hour; electrophoretic mobility shift assay), nuclear translocation of p50/p65 subunits, and cytosolic inhibitor kappaBalpha (IkappaBalpha) degradation. Ang II elicited NF-kappaB-mediated transcription (transfection of a reporter gene) and expression of NF-kappaB-related genes (monocyte chemoattractant protein-1 and angiotensinogen). AT(1) (DUP753) and AT(2) (PD123319 and CGP42112) receptor antagonists inhibited Ang II-induced NF-kappaB DNA binding in a dose-dependent manner ( approximately 85% for each one; 10(-)(5) mol/L at 1 hour). The AT(2) agonist p-aminophenylalanine(6)-Ang II augmented NF-kappaB binding (4.6-fold, 10(-)(9) mol/L at 1 hour), p65 nuclear levels, and transcription of an NF-kappaB reporter gene. AT(1) antagonist markedly inhibited NF-kappaB-mediated transcription and gene expression. Some differences between AT(1)/AT(2) intracellular signals were found. Antioxidants and ceramide inhibitors, but not protein kinase C inhibitors, diminished NF-kappaB activation elicited by both Ang II and the AT(2) agonist, while tyrosine kinase inhibitors only decreased Ang II-induced NF-kappaB activity. Our results demonstrate that Ang II activates NF-kappaB via AT(1) and AT(2), although NF-kappaB-mediated transcription occurred mainly through AT(1). Both receptors share some signaling pathways (oxygen radicals and ceramide); however, tyrosine kinases only participate in AT(1)/NF-kappaB responses. These data provide novel insights into Ang II actions, suggesting a potential implication of the AT(2) in the pathobiology of vascular cells.
Collapse
MESH Headings
- Angiotensin II/pharmacology
- Animals
- Biological Transport/drug effects
- Cell Nucleus/metabolism
- Cells, Cultured
- Cytosol/metabolism
- I-kappa B Proteins/metabolism
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/metabolism
- NF-kappa B/metabolism
- NF-kappa B/physiology
- NF-kappa B p50 Subunit
- Rats
- Receptor, Angiotensin, Type 1
- Receptor, Angiotensin, Type 2
- Receptors, Angiotensin/physiology
- Signal Transduction/physiology
- Transcription Factor RelA
- Transcription, Genetic/drug effects
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Vascular and Renal Research Laboratory, Fundación Jimenez Diaz, Universidad Autónoma Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
35
|
Abstract
BACKGROUND Monocyte infiltration is a common feature of renal diseases. Angiotensin II (Ang II) participates in inflammatory cell infiltration in the kidney. However, the influence of other peptides of the renin-angiotensin system, such as the N-terminal Ang II degradation product Ang III, has not been addressed. METHODS In cultured renal and mononuclear cells, we investigated whether Ang III is involved in monocyte recruitment through the regulation of the chemokine, monocyte chemoattractant protein-1 (MCP-1; Northern blot, Western blot, immunofluorescence, and chemotaxis), and the activation of transcription factors, nuclear factor kappaB (NF-kappaB) and activating protein-1 (AP-1; electrophoretic mobility shift assay). RESULTS In cultured rat mesangial and mononuclear cells, Ang III increased MCP-1 gene expression and protein levels. Supernatants from Ang III-treated mesangial cells showed increased chemoattractant activity for monocytes, which was partially inhibited by the addition of anti-MCP-1 antibody. Ang III elicited a rapid NF-kappaB activation (8-fold, after 30 min), showing a kinetics and intensity similar to that observed with Ang II and tumor necrosis factor-alpha. The maximal NF-kappaB activation was correlated with nuclear translocation of p50 and p65 subunits and disappearance of cytosolic IkappaB. Ang III also activated AP-1 (5-fold, after 18 h), while SP-1 was unchanged. Two NF-kappaB inhibitors abolished the Ang III-induced MCP-1 mRNA expression, suggesting that overexpression of this chemokine is mediated, at least in part, by NF-kappaB activation. CONCLUSIONS Ang III activates the transcription factors NF-kappaB and AP-1 and increases the expression of related genes, such as MCP-1. Our study describes a novel and potent proinflammatory action of this Ang degradation product, expanding the present view of the renin-angiotensin system.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | |
Collapse
|
36
|
Ruiz-Ortega M, Lorenzo O, Ruperez M, Egido J. ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect. Nephrol Dial Transplant 2000; 15:561-5. [PMID: 10809789 DOI: 10.1093/ndt/15.5.561] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Abstract
The vascular extracellular matrix is responsible for the mechanical properties of the vessel wall and is also involved in biologic processes such as cellular adhesion, regulation, and proliferation. Thus, an adequate balance of its components is necessary for the normal functioning of the vasculature. Vascular disorders affect this balance, and this plays a key role in their pathophysiology. Atherogenesis is accompanied by an increase in matrix deposition in response to low-density lipoprotein accumulation. However, this matrix, mainly collagen, also has a protective role by forming a fibrous cap around the lipid core, avoiding contact with blood. A decrease in the amount of collagen will weaken the cap and make it prone to rupture, leading to thrombosis and acute coronary syndromes. In hypertension, the increase in matrix deposition results in vascular stiffness and cardiac dysfunction. In this paper, we discuss the relevance of matrix regulation in these conditions.
Collapse
Affiliation(s)
- J Tuñón
- Department of Cardiology, Universidad Autónoma, Fundación Jiménez Díaz, Avda. Reyes Católicos 2, 28040 Madrid, Spain
| | | | | |
Collapse
|
38
|
Ruiz-Ortega M, Lorenzo O, Egido J. Angiotensin III up-regulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts. Kidney Int Suppl 1998; 68:S41-5. [PMID: 9839282 DOI: 10.1046/j.1523-1755.1998.06811.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Angiotensin (Ang) II is considered the effector peptide of the renin-angiotensin system (RAS) that acts as a renal growth factor. Some studies have shown that the angiotensin degradation product Ang III presents some biological activities, though its role in renal pathology has not been explored. We have observed that in renal interstitial fibroblasts Ang III induces c-fos gene expression, suggesting a potential role of Ang III in the control of cell proliferation. To study the involvement of Ang III in matrix regulation, we determined whether Ang III increased TGF-beta gene expression and fibronectin production in cultured rat mesangial cells and renal interstitial fibroblasts, the main effector cells in glomerular and interstitial fibrosis, respectively. In both cell types, treatment with Ang III (10(-7) M) for six hours up-regulated gene expression of transforming growth factor-beta 1 (TGF-beta 1; 2.3- and 2.2-fold, respectively). This peptide also increased fibronectin production in renal interstitial fibroblasts. All these data suggest that Ang III could contribute to matrix accumulation. Activation of local RAS has been described during renal damage. Renal cells express angiotensinogen mRNA that was up-regulated in response to Ang II and Ang III stimulation, and therefore both peptides may participate in the generation of angiotensin peptides in the kidney. In conclusion, our results suggest that the angiotensin degradation product Ang III could participate in the pathogenesis of key events of renal diseases, supporting the hypothesis that other peptides of the RAS besides Ang II may be involved in renal injury.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Renal Unit, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | |
Collapse
|
39
|
Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998; 161:430-9. [PMID: 9647253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Angiotensin-converting enzyme (ACE) inhibitors reduce macrophage infiltration in several models of renal injury. We approached the hypothesis that angiotensin II (AngII) could be involved in inflammatory cell recruitment during renal damage through the synthesis of monocyte chemoattractant protein-1 (MCP-1). In a model of immune complex nephritis, we observed an up-regulation of renal MCP-1 (mRNA and protein) coincidentally with mononuclear cell infiltration that were markedly reduced by treatment with the ACE inhibitor quinapril. Exposure of cultured rat mesangial cells to AngII increased MCP-1 mRNA expression (2.7-fold) and synthesis (3-fold), similar to that observed with TNF-alpha. Since NF-kappaB is involved in the regulation of MCP-1 gene, we explored whether the effects of AngII were mediated through NF-kappaB activation. Untreated nephritic rats showed increased renal NF-kappaB activity (3.5-fold) that decreased in response to ACE inhibition. In mesangial cells, AngII activated NF-kappaB (4.3-fold), and the NF-kappaB inhibitor pyrrolidine dithiocarbamate abolished the AngII-induced NF-kappaB activation and MCP-1 gene expression. Our results suggest that AngII could participate in the recruitment of mononuclear cells through NF-kappaB activation and MCP-1 expression by renal cells. This could be a novel mechanism that might further explain the beneficial effects of ACE inhibitors in progressive renal diseases.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Renal Unit, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | | | | | | | |
Collapse
|
40
|
Ruiz-Ortega M, Bustos C, Plaza JJ, Egido J. Overexpression of extracellular matrix proteins in renal tubulointerstitial cells by platelet-activating-factor stimulation. Nephrol Dial Transplant 1998; 13:886-92. [PMID: 9568845 DOI: 10.1093/ndt/13.4.886] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND One common feature of renal diseases is the development of interstitial fibrosis, but the mechanism of this process remains undefined. We hypothesized that platelet-activating factor (PAF), a classical acute inflammatory mediator involved in the pathogenesis of renal damage, acts on renal tubulointerstitial cells, contributing to the development of fibrosis. For this reason we evaluated the effect of PAF on matrix regulation and cell-growth-related events in tubulointerstitial cells. METHODS In vitro studies were conducted with two tubulointerstitial cell lines: renal tubuloepithelial cells (NRK 52E) and interstitial fibroblasts (NRK 49F). The effect of PAF on extracellular matrix gene expression was determined by Northern blot. Fibronectin synthesis was quantified by metabolic labelling and immunoprecipitation. Cell growth changes were evaluated by fluorescence-activated cell-sorting analysis (cell cycle and size) and total protein content by 3[H]leucine incorporation. RESULTS In renal tubuloepithelial cells and interstitial fibroblasts, PAF increased fibronectin mRNA expression. PAF-effect on the expression of collagen genes differed depending on the cell type studied. In tubuloepithelial cells there was an increase in type I and IV collagen mRNA levels, while only type I collagen was increased in fibroblasts. The overexpression of matrix proteins induced by PAF was completely blocked by preincubation of cells with the PAF receptor antagonist, BN52021. The PAF-induced upregulation of fibronectin expression was correlated with the increase in fibronectin synthesis. These effects were not associated with an increase in hyperplasia (characterized by changes in cell cycle) either in tubuloepithelial cells or in interstitial fibroblasts. Moreover, PAF did not induce tubular hypertrophy (changes in protein content and cell size). CONCLUSIONS Our data suggest that PAF could be a mediator involved in extracellular matrix accumulation and, therefore, participate in the formation of renal interstitial fibrosis.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Renal Research Laboratory, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | | | |
Collapse
|
41
|
Ruiz-Ortega M, Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997; 52:1497-510. [PMID: 9407495 DOI: 10.1038/ki.1997.480] [Citation(s) in RCA: 137] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The renin-angiotensin system seems to play an important role in the pathogenesis of renal interstitial fibrosis. However, the potential direct effects of angiotensin II (Ang II) on cultured renal fibroblasts have been little studied. We have observed that rat renal interstitial fibroblasts (NRK 49F cell line) possess AT1 receptors coupled to intracellular calcium mobilization. Exposure of these cells to Ang II induced several short and long growth-related metabolic events mediated by the AT1 receptor, including c-fos gene expression, changes in cell cycle and cell proliferation. Activation of interstitial fibroblasts by Ang II could also contribute to extracellular matrix accumulation. Stimulation with Ang II increased mRNA expression of TGF-beta 1, fibronectin and type I collagen. In fact, Ang II enhanced fibronectin production via AT1 receptors by a process depending on autocrine TGF-beta secretion. The mechanism of some Ang II actions (calcium mobilization and fibronectin production) depended on protein kinase C and tyrosine kinase activation. We further investigated whether renal fibroblasts could express some components of the renin-angiotensin system. These cells constitutively expressed the angiotensinogen gene that was up-regulated by Ang II. Collectively, these results indicate that in renal interstitial fibroblasts Ang II causes hyperplasia and extracellular matrix production via the AT1 receptor. Ang II may initiate a positive feedback regulation of fibroblasts growth, inducing the expression of TGF-beta 1 and angiotensinogen genes. Ang II, acting directly on interstitial fibroblasts, may be implicated in the pathogenesis of renal fibrosis.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Renal Unit, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | |
Collapse
|
42
|
Ruiz-Ortega M, Largo R, Bustos C, Gómez-Garre D, Egido J. Platelet-activating factor stimulates gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: role of TGF-beta. J Am Soc Nephrol 1997; 8:1266-75. [PMID: 9259353 DOI: 10.1681/asn.v881266] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Platelet-activating factor (PAF) is a potent inflammatory mediator that participates in the pathogenesis of proteinuria and glomerular damage. However, the role of this lipid in glomerular sclerosis remains unknown. This study examines the effect of PAF on the regulation of extracellular matrix proteins by rat and human mesangial cells. PAF increased in a dose-dependent manner the gene expression of fibronectin and type IV collagen, but not type I collagen. Moreover, an increase in cell-associated and soluble fibronectin synthesis was also seen. These effects were abolished by BN52021 and WEB2086, two different PAF receptor antagonists. Because transforming growth factor (TGF)-beta has been considered a profibrogenic cytokine, this study also evaluated whether PAF effects might be mediated by the production of endogenous TGF-beta. PAF caused an increase in TGF-beta1 mRNA expression (by a protein kinase C-dependent pathway) and TGF-beta activity. Moreover, PAF-induced fibronectin synthesis was totally abolished when an anti-TGF-beta-neutralizing antibody was added to the culture medium, suggesting that PAF stimulates fibronectin synthesis, at least in part, through the induction of TGF-beta. Addition of cycloheximide, a protein synthesis inhibitor, upregulated PAF-induced fibronectin mRNA expression but downregulated PAF-induced TGF-beta1 gene expression, suggesting the existence of different regulatory transcriptional factors of the two proteins. These results suggest that PAF may be implicated in matrix accumulation during renal injury and therefore contribute to the pathogenesis of glomerulosclerosis.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Renal Unit, Fundacion Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | | | | | |
Collapse
|
43
|
Ruiz-Ortega M, Gómez-Garre D, Liu XH, Blanco J, Largo R, Egido J. Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis. J Am Soc Nephrol 1997; 8:756-68. [PMID: 9176845 DOI: 10.1681/asn.v85756] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Angiotensin-converting enzyme (ACE) inhibitors diminish proteinuria and the progression to renal failure in several experimental models of renal injury. Endothelin-1 (ET-1) possesses potent biological actions on renal vessels and has been considered as a potential mediator of renal damage. Because angiotensin II (Ang II) induces ET-1 synthesis in endothelial and mesangial cells, we hypothesized that some of the beneficial effects of the ACE inhibitors could result from the blockade of ET-1 synthesis. In a normotensive model of immune-complex nephritis, in which there exists an increase in renal ACE activity, the effect of the ACE inhibitor quinapril on preproET-1 and ETA receptor mRNA expression, as well as on ET-1 protein levels, was examined in this study. In relation to controls, nephritic rats showed an increase in preproET-1 and ETA receptor gene expression in renal cortex and medulla, coinciding with the maximal renal ACE activity. PreproET-1 mRNA (in situ hybridization) and ET-1 protein (immunohistochemistry) were localized in glomerular capillary walls, mesangial and glomerular epithelial cells, as well as in the brush border of some proximal tubules, and in small vessels. In nephritic rats, there was an increase in preproET-1 mRNA levels and ET-1 protein in all of these areas, without modification of their distribution. The administration of the ACE inhibitor quinapril decreased proteinuria and morphological lesions, preproET-1 gene transcription, and ET-1 protein levels, as well as the ETA receptor mRNA. The results from this study show that in a normotensive model of immune-complex nephritis, there was an overexpression of ET-1 in several structures of the kidney that was downregulated by quinapril administration. The beneficial effect of ACE inhibitors could be a result of the modulation of local production of Ang II and ET-1.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Renal Unit, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | | | | | | | |
Collapse
|
44
|
Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95:1532-41. [PMID: 9118522 DOI: 10.1161/01.cir.95.6.1532] [Citation(s) in RCA: 341] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND The migration of monocytes into the vessel wall is a critical event leading to the development of atherosclerosis. Monocyte chemoattractant protein-1 (MCP-1) is the main chemotactic factor involved in this phenomenon, and nuclear factor-kappa B (NF-kappa B) is one of the nuclear factors controlling its expression. ACE inhibitors have been useful in some experimental models of atherosclerosis. In this work, we addressed the hypothesis that angiotensin II (Ang II) may be implicated in the recruitment of monocytes into the vessel wall through the activation of NF-kappa B and the induction of MCP-1 expression. METHODS AND RESULTS Accelerated atherosclerosis was induced in the femoral arteries of rabbits by endothelial desiccation and atherogenic diet for 7 days. Atherosclerotic vessels exhibited an increase in NF-kappa B-like activity, and p50 and p65 NF-kappa B subunits were identified as components of this activity. MCP-1 (mRNA and protein) was also expressed in the injured vessels coincidently with the neointimal macrophage infiltration. ACE inhibition with quinapril reduced these three parameters. In cultured monocytic and vascular smooth muscle cells. Ang II elicited an increase in NF-kappa B activation and MCP-1 expression that was prevented by preincubation of cells with pyrrolidinedithiocarbamate, an inhibitor of NF-kappa B activation. CONCLUSIONS The present data support a role for Ang II in neointimal monocyte infiltration through NF-kappa B activation and MCP-1 expression in a model of accelerated atherosclerosis in rabbits. Our results suggest that ACE inhibitors may have a beneficial effect in early atherosclerosis.
Collapse
Affiliation(s)
- M Hernández-Presa
- Research Laboratory, Fundación Jiménez Díaz, Autonoma University, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
45
|
González-Cuadrado S, Bustos C, Ruiz-Ortega M, Ortiz A, Guijarro C, Plaza JJ, Egido J. Expression of leucocyte chemoattractants by interstitial renal fibroblasts: up-regulation by drugs associated with interstitial fibrosis. Clin Exp Immunol 1996; 106:518-22. [PMID: 8973621 PMCID: PMC2200627 DOI: 10.1046/j.1365-2249.1996.d01-864.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Interstitial inflammation is a strong predictor of long-term renal damage. The potential role of renal interstitial fibroblasts in recruitment of inflammatory leucocytes into the interstitium is unclear. We have thus studied the mRNA expression of several leucocyte chemotactic factors by rat renal interstitial fibroblasts and its modulation by cytokines. In addition, the effects of two unrelated drugs associated with the development of interstitial fibrosis, namely puromycin aminonucleoside (PAN) and cyclosporin A (CsA), were also studied. Rat renal interstitial fibroblasts showed constitutive mRNA expression for the chemokines monocyte chemoattractant protein 1 (MCP-1) and interferon-inducible protein 10 (IP-10). In addition, these cells also exhibited constitutive mRNA expression for cyclophilin B, an immunophilin recently found to have leucocyte chemoattractant properties. The inflammatory cytokine tumour necrosis factor-alpha up-regulated IP-10 and MCP-1 mRNA expression (10- and four-fold, respectively), but had no effect on cyclophilin B mRNA levels. IP-10 and MCP-1 produced about a four-fold increase in MCP-1 and cyclophilin B mRNA expression, but did not affect IP-10 mRNA. PAN caused an augmentation in IP-10, MCP-1 and cyclophilin B mRNA levels (12-, 9.5, and two-fold, respectively), while CsA increased only cyclophilin B mRNA in a dose-dependent manner. In conclusion, rat renal interstitial fibroblasts express mRNA for chemotactic factors and this expression is up-regulated by inflammatory cytokines, PAN and CsA. The present findings suggest that renal interstitial fibroblasts may play an active role in the recruitment of inflammatory leucocytes into the interstitium.
Collapse
Affiliation(s)
- S González-Cuadrado
- Renal Research Laboratory, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
46
|
Gómez-Garre D, Ruiz-Ortega M, Ortego M, Largo R, López-Armada MJ, Plaza JJ, González E, Egido J. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996; 27:885-92. [PMID: 8613264 DOI: 10.1161/01.hyp.27.4.885] [Citation(s) in RCA: 115] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Mesangial cell growth and accumulation of extracellular matrix proteins constitute key features of progressive glomerular injury. Endothelin-1 (ET-1) and angiotensin II (Ang II), two potent vasoconstrictor agents, evoke a number of similar responses in mesangial cells. In rat mesangial cells, we compared ET-1 and Ang II effects on matrix protein production and cell proliferation as well as the potential interaction between the two hormones. When cells in 0.5% fetal calf serum were incubated for 24 hours with various concentrations of ET-1 or Ang II, both peptides stimulated, in a dose-dependent manner, fibronectin and type IV collagen mRNA expression, fibronectin synthesis, and mitogenesis. Incubation with specific receptor antagonists of both hormones demonstrated that endothelin subtype A (ETA) and angiotensin type 1 (AT1) receptors were involved. Preincubation of cells with two different protein kinase C inhibitors or with a neutralizing anti-transforming growth factor-beta antibody, but not an unrelated IgG, diminished the peptide-induced fibronectin synthesis. A dual interrelation seems to exist between ET-1 and Ang II. Thus, the AT1 receptor antagonist losartan and the angiotensin-converting enzyme inhibitors quinaprilat and captopril diminished the ET-1-mediated effects, whereas, the ETA receptor antagonist BQ-123 diminished the Ang II-induced fibronectin synthesis and mesangial cell proliferation. Our results suggest that ET-1 and Ang II stimulate matrix protein synthesis and mesangial cell mitogenesis through ETA and AT1 receptors, respectively, by complicated mechanisms, implicating protein kinase C activation, synthesis of transforming growth factor-beta, and release of one peptide by the other. These data could be important for a better understanding of the participation of vasoactive substances in the pathogenesis of glomerulosclerosis.
Collapse
Affiliation(s)
- D Gómez-Garre
- Renal Research Laboratory, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Ruiz-Ortega M, González S, Serón D, Condom E, Bustos C, Largo R, González E, Ortiz A, Egido J. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995; 48:1778-91. [PMID: 8587237 DOI: 10.1038/ki.1995.476] [Citation(s) in RCA: 96] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
We studied the effect of the angiotensin converting enzyme (ACE) inhibitor, quinapril, on the clinical and morphological lesions of a normotensive model of immune complex nephritis. Untreated rats developed massive nephrotic syndrome, intense cell proliferation and glomerular and tubulointerstitial lesions. In the renal cortex of nephritic rats there was a significant increase in gene expression of TGF-beta 1, fibronectin and collagens, and ACE activity. Systolic blood pressure remained normal with progression of the disease. Administration of quinapril for three weeks to animals with glomerular lesions (proteinuria 20 to 50 mg/day) avoided the development of intense proteinuria (79 +/- 28 vs. 589 +/- 73 mg/day, P < 0.001) and decreased cell proliferation, glomerulosclerosis, tubulointerstitial lesions, and inflammatory infiltrates. Cortical gene expression of TGF-beta 1 and matrix proteins was also diminished. ACE activity was inhibited by 68% in renal cortex. These results show that quinapril administration to normotensive rats with immune complex nephritis decreases proteinuria and glomerular and tubulointerstitial lesions, probably modulating the local angiotensin II generation and its effects on cell growth, TGF beta and matrix protein synthesis.
Collapse
Affiliation(s)
- M Ruiz-Ortega
- Renal Unit, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Bustos C, González-Cuadrado S, Ruiz-Ortega M, Gómez-Guerrero C, González E, Plaza JJ, Egido J. Cyclosporin A (CsA) modulates the glomerular production of inflammatory mediators and proteoglycans in experimental nephrosis. Clin Exp Immunol 1995; 102:608-13. [PMID: 8536380 PMCID: PMC1553369 DOI: 10.1111/j.1365-2249.1995.tb03860.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Nephrosis is characterized by glomerular epithelial cell injury and a decrease in the glomerular basement membrane (GBM) proteoglycan content. Although CsA is a useful treatment for a group of patients with this disease, its mechanism of action is unclear. We have previously shown that in experimental nephrosis there is an increase in the glomerular production of tumour necrosis factor-alpha (TNF-alpha) and platelet-activating factor (PAF). Here we have studied the effect of CsA on kidney generation of TNF-alpha and PAF in puromycin aminonucleoside (PAN) nephrosis as well as on the synthesis of proteoglycans by cultured glomerular epithelial cells. Rats receiving CsA had, on day 8 of PAN injection, a significant reduction in proteinuria, blood cholesterol levels and in interstitial mononuclear cells. A diminution in glomerular production and urinary excretion of TNF-alpha and PAF was also noted. In in vitro studies, at 24 h of incubation PAF and TNF-alpha induced in glomerular epithelial cells a significant decrease in proteoglycan synthesis. Neither PAF nor TNF-alpha had any significant effect on glomerular epithelial cell proliferation. CsA alone induced a dose-response increase in proteoglycan synthesis and a slight decrease in cell proliferation. CsA also reversed the inhibitory effect of PAF and TNF-alpha on proteoglycan synthesis. However, CsA did not alter the pattern of proteoglycan production, remaining around 50% chondroitinase ABC-, 15% heparitinase-sensitive. Our results indicate that PAF and TNF-alpha could be implicated in the pathogenesis of nephrosis through the inhibition of proteoglycan synthesis by glomerular epithelial cells. The beneficial effect of CsA in nephrosis may be due to the recovery of the GBM charge selectivity caused by the normalization of glomerular PAF and TNF-alpha synthesis and the increase in proteoglycan synthesis by glomerular epithelial cells.
Collapse
Affiliation(s)
- C Bustos
- Renal Research Laboratory, Fundación Jiménez Díaz, Autonoma University, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|